The Edison System for Treatment of Benign Prostatic Hyperplasia (BPH) Using Histotripsy
- Sponsor
- HistoSonics, Inc.
- Study ID
- NCT07214675
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- MALE
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- HistoSonics Edison System — DEVICEThe HistoSonics Edison System is intended for the non-invasive mechanical destruction of prostate tissue for the treatment of BPH using histotripsy, a non-thermal, mechanical process of focused ultrasound.
Study Details
The purpose of this trial is to evaluate the safety of histotripsy using the HistoSonics Edison System for treatment of BPH.
Key Dates
- Start date
- Mar 20, 2026
- Status verified
- Oct 2025
- Primary completion
- May 31, 2027
- Completion
- Oct 31, 2027
Study Design
- Enrollment
- 80 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: HistoSonics Edison System
Primary Outcome Measure
Number of Index-Procedure Related Adverse Events Classified by Clavien-Dindo Classification and Common Terminology Criteria for Adverse Events (CTCAE) [ Time Frame: 30 days post histotripsy procedure ]
Central Contacts
- Kelly Erickson612-965-8895
Related Studies
- 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI TherapyRecruiting · Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Customized TULSA-PRO Ablation RegistryRecruiting · Profound Medical Inc. · West Hills, California
- BPH Global RegistryRecruiting · Société Internationale d'Urologie · Los Angeles, California
- Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported OutcomesRecruiting · Northwestern University · Glenview, Illinois